FDA clears AI assessor of stricken dense brain tissue
RapidAI of Menlo Park, Calif., has received the FDA’s go-ahead to market a new tool within its platform that automatically diagnoses stroke and brain injury in hyperdense brain tissue imaged with unenhanced CT.
Called Rapid Hyperdensity, the AI-powered tool was designed to speed triage and transfer decisions, the company says in a July 21 announcement.
Rapid says the software is the only comprehensive neurovascular decision support platform to offer such functionality for care of patients with head trauma and hemorrhagic stroke.
Results can be viewed in email, PACS or Rapid’s mobile app.
The announcement quotes Alejandro Spiotta, MD, director of neuroendovascular surgery at the Medical University of South Carolina.
“Detection of intracranial hemorrhage (ICH) via AI can save lives by helping to speed up diagnosis and accelerate transfer to the best physician and hospital that can take care of the patient,” Spiotta says. “With the addition of automatic hyperdense volume measurement, physicians can more easily track volume over time and help quickly identify which patients may require an intervention. This is an exciting time for those of us treating ICH.”
Full announcement here.
Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.